Asia Pacific In Vivo Cro Market Size & Outlook, 2024-2030
Asia Pacific in vivo cro market, 2018-2030 (US$M)
Related Markets
Asia Pacific in vivo cro market highlights
- The Asia Pacific in vivo cro market generated a revenue of USD 458.1 million in 2023.
- The market is expected to grow at a CAGR of 8.7% from 2024 to 2030.
- In terms of segment, small molecule was the largest revenue generating modality type in 2023.
- Large Molecule is the most lucrative modality type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 458.1 million |
| Market revenue in 2030 | USD 823.6 million |
| Growth rate | 8.7% (CAGR from 2023 to 2030) |
| Largest segment | Small molecule |
| Fastest growing segment | Large Molecule |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Small Molecule, Large Molecule |
| Key market players worldwide | IQVIA Holdings Inc, JSR Corp, Taconic Biosciences, Evotec SE, Janvier Labs, Charles River Laboratories International Inc, Icon PLC, Labcorp Holdings Inc, PAREXEL, GemPharmatech, PsychoGenics, Biocytogen, SMO-Group |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 9.9% of the global in vivo cro market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 823.6 million by 2030.
Small molecule was the largest segment with a revenue share of 63.61% in 2024. Horizon Databook has segmented the Asia Pacific in vivo cro market based on small molecule, large molecule covering the revenue growth of each sub-segment from 2018 to 2030.
Growth in the region is due to several factors, including the cost-effectiveness of CROs across India & China, economic development, and advanced healthcare infrastructure. Increasing partnerships and investments by CROs and the growing percentage of outsourcing in vivo services to emerging economies are some factors expected to propel growth during the forecast period.
Emerging markets in the Asia Pacific, such as China, India, and South Korea, are witnessing significant growth in the pharmaceutical and biotechnology sectors. These markets offer substantial opportunities for in vivo CROs to expand their operations and tap into new client bases.
Moreover, the region has witnessed significant technological advancements, such as state-of-the-art imaging technologies, genomics, and precision medicine. These in vivo CROs in the region can leverage these advancements to provide cutting-edge research services and stay at the forefront of biomedical innovation.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
In Vivo CRO Market Scope
In Vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific in vivo cro market size, by country, 2018-2030 (US$M)
Asia Pacific In Vivo CRO Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
